NEW YORK – Shanghai-based LianBio on Tuesday said that it has received permission from regulators in China to begin evaluating infigratinib in patients with FGFR2 gene-amplified, locally advanced, or metastatic gastric or gastroesophageal junction cancer.
The multi-center, single-arm, Phase IIa trial, which the China National Medical Products Administration's Center for Drug Evaluation has cleared, is designed to assess the safety, efficacy, and pharmacokinetic profile of the selective pan-FGFR inhibitor infigratinib in this patient population.